Cannabidiol for Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Stem Cell Transplantation
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Graft versus host disease (GVHD) is one of the major causes of death in patients undergoing
allogeneic hematopoietic cell transplantation. Despite prophylactic measures, the incidence
of acute GVHD is estimated at 40-60% among patients receiving transplant from HLA-identical
sibling donors, and may even reach 75% in patients receiving HLA-matched unrelated
transplants. More effective prevention and treatment strategies are needed.
The immunomodulatory and anti-inflammatory properties of Cannabinoids have been shown in
animal models of various inflammatory diseases including multiple sclerosis, inflammatory
bowel disease and rheumatoid arthritis.
Cannabidiol is a major non-psychoactive cannabinoid, which has potent anti-inflammatory and
immunosuppressive effects.
As such, it may reduce the incidence and severity of GVHD after allogeneic stem cell
transplantation.